Sort
17,288 grants matching “multiple sclerosis”
Role of T Cell Mediated Immunity In Emotion And Stress Responsiveness
$225,000Leonardo H Tonelli · University Of Maryland Baltimore · R21 · FY2011 · MH
STTR Phase I: Active Transport of Caffeine through a Blood-Brain Barrier Model
$225,000Andrew J Makowski · Nistron, L.L.C. · · FY2020 · TIP
Development of a cell based assay to assess antigen specific tolerance
$225,000Brianna Mullins · Salus Discovery, Llc · R43 · FY2018 · AI
A Novel Probiotic for the Treatment of Rheumatoid Arthritis
$225,000Neil A Fanger · Virtici, Llc · R43 · FY2017 · AR
DEFINING AN ORAL THERAPEUTIC FOR MULTIPLE SCLEROSIS
$225,000Cell Therapeutics, Inc. · R42 · FY2000 · NS
Genetic toolkit for genome editing of the Lactobacillus genus.
$224,999Ewa Lis · Koliber Biosciences, Inc. · R43 · FY2018 · GM
A Single Antiviral to Treat Multiple Opportunistic Infections
$224,999Emre Koyuncu · Evrys Bio, Llc · R43 · FY2014 · AI
An Antiviral to Treat Progressive Multifocal Leukoencephalopathy_(PML)
$224,999Stacy Remiszewski · Evrys Bio, Llc · R43 · FY2015 · AI
SBIR Phase I: A Patient-Centered Wearable System to Enable Data-Driven Decisions in Neuromuscular Disorders
$224,996Dexter Ang · Pison Technology Inc · · FY2018 · TIP
Monoclonal antibody for autoimmune disease
$224,981James W Larrick · Panorama Research, Inc. · R43 · FY2015 · AI
Emerging role of exosomes derived from peripheral immune cells in regulation of neuroinflammation in response to neural injury
$224,978Yi Ren · Florida State University · R21 · FY2022 · NS
Delivery of peptides for inducing voiding associated with neurological retention
$224,946Lesley Marson · Dignify Therapeutics, Llc · R41 · FY2015 · NS
Development of a cannabinoid yeast factory: improving geranyl pyrophosphate production through metabolic engineering
$224,920Anthony Neal Farina · Librede, Inc. · R43 · FY2016 · GM
Immune Modulation During Acute Lyme Disease Infection as the Result of Aberrant Immunoglobulin Glycosylation
$224,908Mary Ann Comunale · Drexel University · R21 · FY2023 · AI
Developing a Nrf2 activator for the treatment of COPD
$224,896Graham P Allaway · Cureveda, Llc · R41 · FY2014 · HL
Preclinical and neuroimmunologic study of RTL1000 for methamphetamine addiction
$224,886Jennifer M Loftis · Virogenomics Biodevelopment, Inc. · R41 · FY2015 · DA
Developing a Nrf2 activator for the treatment of scleroderma
$224,858Graham P Allaway · Cureveda, Llc · R41 · FY2014 · AR
Unbiased longitudinal neuromorphometry for clinical decision support
$224,843Paul Wighton · Corticometrics, Llc · R42 · FY2019 · AG
Development of cGMP Manufacturing Process for CBD
$224,841Trevor P. Castor · Aphios Corporation · R44 · FY2014 · DA
Cannabinoid Signaling System in Microglial Cell
$224,822University Of Washington · R01 · FY2001 · DA
Sustained 3-Month Delivery of Tizanidine for Maintenance Treatment of Moderate to Severe Spasticity
$224,798Frank J Martin · Delpor, Inc. · R43 · FY2019 · NS
Software Platform to Stratify Patients for Treatment Arm Randomization in Human Clinical Trials using Patient-Level Predictive Models
$224,796David L Ennist · Origent Data Sciences, Inc. · R43 · FY2017 · TR
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects
$224,796Arthur A. Vandenbark · Virogenomics Biodevelopment, Inc. · R41 · FY2016 · AI
Project 4: Willis
$224,469Colin Willis · University Of New England · P20 · FY2014 · GM
A novel genetic tool to investigate T cell development and function
$224,375Yongqiang Feng · St. Jude Children'S Research Hospital · R21 · FY2020 · AI